Filing Details
- Accession Number:
- 0000897423-25-000023
- Form Type:
- 13G Filing
- Publication Date:
- 2025-02-12 19:00:00
- Filed By:
- BRATTON DOUGLAS K
- Company:
- Aquestive Therapeutics Inc. (NASDAQ:AQST)
- Filing Date:
- 2025-02-13
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Beneficially Owned Number of Shares | Beneficially Owned Number of Aggregate Shares | Percent of Class |
|---|---|---|---|
| BRATTON DOUGLAS K | 0 | 10,077,434 | 11.1% |
| MonoLine RX II, L.P. | 0 | 3,468,747 | 3.8% |
| MonoLine RX III, L.P. | 0 | 2,657,943 | 2.9% |
| MonoLine RX, L.P. | 0 | 1,688,639 | 1.9% |
| MonoLine Partners, L.P. | 0 | 1,948,578 | 2.1% |
| MonoSol Rx Genpar, L.P. | 0 | 47,051 | 0.1% |
Filing
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
(Amendment No. 4)
|
Aquestive Therapeutics, Inc. (Name of Issuer) |
Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) |
03843E104 (CUSIP Number) |
12/31/2024 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
| Rule 13d-1(c)
|
 Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. | 03843E104 |
| 1 | Names of Reporting Persons
BRATTON DOUGLAS K | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
10,077,434.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
11.1 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person: Bratton Capital Management L.P. is the general partner of each of the Reporting Persons except for MonoSol Rx Genpar, L.P., the general partner of which is Bratton Capital Inc., which, in turn, is the general partner of Bratton Capital Management L.P. Douglas K. Bratton ("DKB"), as the sole director and President of Bratton Capital Inc., exercises voting and dispositive power over 9,810,958 of the 10,023,384 shares reported herein. The number 10,023,384 also includes 212,426 shares owned directly by DKB or by family trusts and entities.
The number 10,077,434 includes 212,426 shares either owned directly by DKB or held by family trusts and entities, and 54,050 shares that DKB currently has the right to acquire under vested director stock options. It does not include 2,727 shares owned by DKB's spouse, with respect to which DKB disclaims beneficial ownership.
SCHEDULE 13G
|
| CUSIP No. | 03843E104 |
| 1 | Names of Reporting Persons
MonoLine RX II, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
3,468,747.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
3.8 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13G
|
| CUSIP No. | 03843E104 |
| 1 | Names of Reporting Persons
MonoLine RX III, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,657,943.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
2.9 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13G
|
| CUSIP No. | 03843E104 |
| 1 | Names of Reporting Persons
MonoLine RX, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,688,639.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
1.9 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13G
|
| CUSIP No. | 03843E104 |
| 1 | Names of Reporting Persons
MonoLine Partners, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,948,578.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
2.1 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13G
|
| CUSIP No. | 03843E104 |
| 1 | Names of Reporting Persons
MonoSol Rx Genpar, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
47,051.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
0.1 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13G
|
| Item 1. | ||
| (a) | Name of issuer:
Aquestive Therapeutics, Inc. | |
| (b) | Address of issuer's principal executive offices:
30 TECHNOLOGY DRIVE, WARREN, NEW JERSEY, 07059. | |
| Item 2. | ||
| (a) | Name of person filing:
Pursuant to Regulation 13D-G of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended (the "Act"), the undersigned hereby files this Schedule 13G Statement on behalf of Douglas K. Bratton ("DKB"), MonoLine Rx II, L.P., a Texas limited partnership ("MonoLine II"), MonoLine Rx III, L.P., a Texas limited partnership ("MonoLine III"), MonoLine Rx, L.P., a Texas limited partnership ("MonoLine Rx"), MonoLine Partners, L.P., a Texas limited partnership ("Monoline"), and MonoSol Rx Genpar, L.P., a Texas limited partnership ("Genpar"), all of such persons and entities being referred to herein as the "Reporting Persons." Additionally, information is included herein with respect to the following persons (collectively, the "Controlling Persons"): Bratton Capital Management L.P., a Texas limited partnership ("Bratton Capital"), and Bratton Capital Inc., a Texas corporation ("Bratton Inc."). The Reporting Persons and the Controlling Persons are sometimes hereinafter collectively referred to as the "Item 2 Persons." The Item 2 Persons are making this single, joint filing because they may be deemed to constitute a "group" within the meaning of Section 13(d)(3) of the Act, although neither the fact of this filing nor anything contained herein shall be deemed to be an admission by the Item 2 Persons that such a group exists. | |
| (b) | Address or principal business office or, if none, residence:
The address of the principal business office of each of the Item 2 Persons is 201 Main Street, Suite 2100, Fort Worth, Texas 76102. | |
| (c) | Citizenship:
All of the natural persons listed in Item 2(a) are citizens of the United States of America. | |
| (d) | Title of class of securities:
Common Stock, Par Value $0.001 Per Share | |
| (e) | CUSIP No.:
03843E104 | |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| (a) | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
| |
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
| |
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
| |
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
| |
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
| |
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
| |
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
| |
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
| |
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
| |
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: | |
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
| |
| Item 4. | Ownership | |
| (a) | Amount beneficially owned:
DKB
Because of his position as sole director and President of Bratton Inc., which is the general partner of both Genpar and Bratton Capital, which, in turn, is the general partner or manager of each of the other Reporting Persons, and his ownership of 266,476 shares held by him directly or by entities and trusts for the benefit of his immediate family, DKB may, pursuant to Rule 13d-3 of the Act, be deemed to be the beneficial owner of an aggregate of 10,077,434 shares of the Stock.
MonoLine II
The aggregate number of shares of the Stock that MonoLine II owns beneficially, pursuant to Rule 13d-3 of the Act, is 3,468,747.
MonoLine III
The aggregate number of shares of the Stock that MonoLine III owns beneficially, pursuant to Rule 13d-3 of the Act, is 2,657,943.
MonoLine Rx
The aggregate number of shares of the Stock that MonoLine Rx owns beneficially, pursuant to Rule 13d-3 of the Act, is 1,688,639.
MonoLine
The aggregate number of shares of the Stock that MonoLine owns beneficially, pursuant to Rule 13d-3 of the Act, is 1,948,578.
Genpar
The aggregate number of shares of the Stock that Genpar owns beneficially, pursuant to Rule 13d-3 of the Act, is 47,051.
Bratton Capital
Because of its position as the general partner of each of MonoLine II, MonoLine III, MonoLine Rx, and MonoLine, Bratton Capital may, pursuant to Rule 13d-3 of the Act, be deemed to be the beneficial owner of 9,763,907 shares of the Stock.
Bratton Inc.
Because of its position as the general partner of both Genpar and Bratton Capital, Bratton Inc. may, pursuant to Rule 13d-3 of the Act, be deemed to be the beneficial owner of 9,810,958 shares of the Stock.
To the best of the knowledge of the Reporting Persons, other than as set forth above, none of the persons named in Item 2 herein is the beneficial owner of any shares of the Stock. | |
| (b) | Percent of class:
DKB
DKB may be deemed to be the beneficial owner of approximately 11.1% of the outstanding shares of the Stock.
MonoLine II
MonoLine II owns approximately 3.8% of the outstanding shares of the Stock.
MonoLine III
MonoLine III owns approximately 2.9% of the outstanding shares of the Stock.
MonoLine Rx
MonoLine Rx owns approximately 1.9% of the outstanding shares of the Stock.
MonoLine
MonoLine owns approximately 2.1% of the outstanding shares of the Stock.
Genpar
Genpar owns approximately 0.1% of the outstanding shares of the Stock.
Bratton Capital
Bratton Capital may be deemed to be the beneficial owner of approximately 10.7% of the outstanding shares of the Stock.
Bratton Inc.
Bratton Inc. may be deemed to be the beneficial owner of approximately 10.8% of the outstanding shares of the Stock.
To the best of the knowledge of the Reporting Persons, other than as set forth above, none of the persons named in Item 2 herein is the beneficial owner of any shares of the Stock. | |
| (c) | Number of shares as to which the person has:
| |
| (i) Sole power to vote or to direct the vote:
DKB
DKB has the sole power to vote or to direct the vote of an aggregate of 10,023,384 shares of the Stock, including 9,810,958 shares in his capacity as the sole director and President of Bratton Inc., which is the general partner of both Genpar and Bratton Capital.
MonoLine II
Acting through its general partner, MonoLine II has the sole power to vote or to direct the vote of 3,468,747 shares of the Stock.
MonoLine III
Acting through its general partner, MonoLine III has the sole power to vote or to direct the vote of 2,657,943 shares of the Stock.
MonoLine Rx
Acting through its general partner, MonoLine Rx has the sole power to vote or to direct the vote of 1,688,639 shares of the Stock.
MonoLine
Acting through its general partner, MonoLine has the sole power to vote or to direct the vote of 1,948,578 shares of the Stock.
Genpar
Acting through its general partner, Genpar has the sole power to vote or to direct the vote of 47,051 shares of the Stock.
Bratton Capital
In its capacity as the general partner of each of MonoLine II, MonoLine III, MonoLine Rx, and MonoLine, Bratton Capital has the sole power to vote or to direct the vote of an aggregate of 9,763,907 shares of the Stock.
Bratton Inc.
In its capacity as (i) the general partner of Genpar, and (ii) the general partner of Bratton Capital, Bratton Inc. has the sole power to vote or to direct the vote of an aggregate of 9,810,958 shares of the Stock. | ||
| (ii) Shared power to vote or to direct the vote:
DKB
DKB has no shared power to vote or to direct the vote of any shares of the Stock.
MonoLine II
MonoLine II has no shared power to vote or to direct the vote of any shares of the Stock.
MonoLine III
MonoLine III has no shared power to vote or to direct the vote of any shares of the Stock.
MonoLine Rx
MonoLine Rx has no shared power to vote or to direct the vote of any shares of the Stock.
MonoLine
MonoLine has no shared power to vote or to direct the vote of any shares of the Stock.
Genpar
Genpar has no shared power to vote or to direct the vote of any shares of the Stock.
Bratton Capital
Bratton Capital has no shared power to vote or to direct the vote of any shares of the Stock.
Bratton Inc.
Bratton Inc. has no shared power to vote or to direct the vote of any shares of the Stock. | ||
| (iii) Sole power to dispose or to direct the disposition of:
DKB
DKB has the sole power to dispose or to direct the disposition of an aggregate of 10,023,384 shares of the Stock, including 9,810,958 shares in his capacity as the sole director and President of Bratton Inc., which is the general partner of both Genpar and Bratton Capital.
MonoLine II
Acting through its general partner, MonoLine II has the sole power to dispose or to direct the disposition of 3,468,747 shares of the Stock.
MonoLine III
Acting through its general partner, MonoLine III has the sole power to dispose or to direct the disposition of 2,657,943 shares of the Stock.
MonoLine Rx
Acting through its general partner, MonoLine Rx has the sole power to dispose or to direct the disposition of 1,688,639 shares of the Stock.
MonoLine
Acting through its general partner, MonoLine has the sole power to dispose or to direct the disposition of 1,948,578 shares of the Stock.
Genpar
Acting through its general partner, Genpar has the sole power to dispose or to direct the disposition of 47,051 shares of the Stock.
Bratton Capital
In its capacity as the general partner of each of MonoLine II, MonoLine III, MonoLine Rx, and MonoLine, Bratton Capital has the sole power to dispose or to direct the disposition of an aggregate of 9,763,907 shares of the Stock.
Bratton Inc.
In its capacity as (i) the general partner of Genpar, and (ii) the general partner of Bratton Capital, Bratton Inc. has the sole power to dispose or to direct the disposition of an aggregate of 9,810,958 shares of the Stock. | ||
| (iv) Shared power to dispose or to direct the disposition of:
DKB
DKB has no shared power to dispose or to direct the disposition of any shares of the Stock.
MonoLine II
MonoLine II has no shared power to dispose or to direct the disposition of any shares of the Stock.
MonoLine III
MonoLine III has no shared power to dispose or to direct the disposition of any shares of the Stock.
MonoLine Rx
MonoLine Rx has no shared power to dispose or to direct the disposition of any shares of the Stock.
MonoLine
MonoLine has no shared power to dispose or to direct the disposition of any shares of the Stock.
Genpar
Genpar has no shared power to dispose or to direct the disposition of any shares of the Stock.
Bratton Capital
Bratton Capital has no shared power to dispose or to direct the disposition of any shares of the Stock.
Bratton Inc.
Bratton Inc. has no shared power to dispose or to direct the disposition of any shares of the Stock. | ||
| Item 5. | Ownership of 5 Percent or Less of a Class. | |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
| Item 8. | Identification and Classification of Members of the Group. | |
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
See attached exhibit. | ||
| Item 9. | Notice of Dissolution of Group. | |
Not Applicable
| ||
| Item 10. | Certifications: |
Not Applicable
|
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit Information
|
Item 8. Exhibit |